Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22 modified FK520 analog against C. neoformans
Fungal infections are of mounting global concern, and the current limited treatment arsenal poses challenges when treating such infections. In particular, infections by Cryptococcus neoformans are associated with high mortality, emphasizing the need for novel therapeutic options. Calcineurin is a protein phosphatase that mediates fungal stress responses, and calcineurin inhibition by the natural product FK506 blocks C. neoformans growth at 37°C. Calcineurin is also required for pathogenesis. However, because calcineurin is conserved in humans, and inhibition with FK506 results in immunosuppression, the use of FK506 as an anti-infective agent is precluded. We previously elucidated the structures of multiple fungal calcineurin-FK506-FKBP12 complexes and implicated the C-22 position on FK506 as a key point for differential modification of ligand inhibition of the mammalian versus fungal target proteins. Through in vitro antifungal and immunosuppressive testing of FK520 (a natural analog of FK506) derivatives, we identified JH-FK-08 as a lead candidate for further antifungal development. JH-FK-08 exhibited significantly reduced immunosuppressive activity and both reduced fungal burden and prolonged survival of infected animals. JH-FK-08 exhibited additive activity in combination with fluconazole in vivo . These findings further advance calcineurin inhibition as an antifungal therapeutic approach.
Importance: Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited and development of antifungal drugs has been hindered by the evolutionary conservation between fungi and the human host. With rising resistance to the current antifungal arsenal and an increasing at-risk population, there is an urgent need for the development of new antifungal compounds. The FK520 analogs described in this study display potent antifungal activity as a novel class of antifungals centered on modifying an existing orally-active FDA approved therapy. This research advances the development of much needed newer antifungal treatment options with novel mechanisms of action.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 11. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rivera, Angela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 23.12.2023 published: Electronic UpdateIn: mBio. 2023 Sep 22;:e0181023. - PMID 37737622 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.06.05.543712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358348226 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358348226 | ||
| 003 | DE-627 | ||
| 005 | 20231227140304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.06.05.543712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1236.xml |
| 035 | |a (DE-627)NLM358348226 | ||
| 035 | |a (NLM)37333270 | ||
| 035 | |a (PII)2023.06.05.543712 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rivera, Angela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22 modified FK520 analog against C. neoformans |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: mBio. 2023 Sep 22;:e0181023. - PMID 37737622 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Fungal infections are of mounting global concern, and the current limited treatment arsenal poses challenges when treating such infections. In particular, infections by Cryptococcus neoformans are associated with high mortality, emphasizing the need for novel therapeutic options. Calcineurin is a protein phosphatase that mediates fungal stress responses, and calcineurin inhibition by the natural product FK506 blocks C. neoformans growth at 37°C. Calcineurin is also required for pathogenesis. However, because calcineurin is conserved in humans, and inhibition with FK506 results in immunosuppression, the use of FK506 as an anti-infective agent is precluded. We previously elucidated the structures of multiple fungal calcineurin-FK506-FKBP12 complexes and implicated the C-22 position on FK506 as a key point for differential modification of ligand inhibition of the mammalian versus fungal target proteins. Through in vitro antifungal and immunosuppressive testing of FK520 (a natural analog of FK506) derivatives, we identified JH-FK-08 as a lead candidate for further antifungal development. JH-FK-08 exhibited significantly reduced immunosuppressive activity and both reduced fungal burden and prolonged survival of infected animals. JH-FK-08 exhibited additive activity in combination with fluconazole in vivo . These findings further advance calcineurin inhibition as an antifungal therapeutic approach | ||
| 520 | |a Importance: Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited and development of antifungal drugs has been hindered by the evolutionary conservation between fungi and the human host. With rising resistance to the current antifungal arsenal and an increasing at-risk population, there is an urgent need for the development of new antifungal compounds. The FK520 analogs described in this study display potent antifungal activity as a novel class of antifungals centered on modifying an existing orally-active FDA approved therapy. This research advances the development of much needed newer antifungal treatment options with novel mechanisms of action | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Lim, Won Young |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Eunchong |e verfasserin |4 aut | |
| 700 | 1 | |a Dome, Patrick A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoy, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Spasojevic, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Averette, Anna Floyd |e verfasserin |4 aut | |
| 700 | 1 | |a Pina-Oviedo, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Juvvadi, Praveen R |e verfasserin |4 aut | |
| 700 | 1 | |a Steinbach, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Ciofani, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Jiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Heitman, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 11. Juli |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:11 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.06.05.543712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 11 |c 07 | ||